HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

A compound with the unpresuming designation of EBC-46 has made a splash in recent years for its cancer-fighting prowess. Now ...

A new chemical compound has been making a big impression in the fight against cancer in recent years. Now it seems EBC-46, otherwise known as tigilanol tiglate, may also have immense potential for ...

Curing HIV will be harder than curing cancer. Apart from a few 'miracle' cases, antiretrovirals only suppress HIV, they don't ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Pseudoscience has recently been reemerging in the US. While much of it concerns vaccines, an "oldie" is again making the ...

Stanford researchers highlight the potential of EBC-46, a compound derived from Australia’s blushwood tree, in eradicating HIV. Acting as a potent latency-reversing agent, EBC-46 activates dormant ...

Flushing HIV out into the open For the new study, the researchers set out to examine EBC-46's value as a "latency reversing agent." These agents kickstart certain pathways in latent cells infected ...

2024 — An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new study. By targeting infected cells in the brain ...

Frazer School student Sophia Rong’s passion for science began in seventh grade at Lincoln Middle School when she was assigned ...

Determinants of HIV cell tropism & chemokine receptor usage The V3 loop of HIV-1 gp120 is a primary determinant of cell tropism and chemokine receptor usage, whereas the V1/V2 region is involved ...